TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25825853
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) with polyethylene glycol
Study: 20624812
Drug: Short-course intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course intravenous antibiotic treatment (≤3 days)
Study: 20624812
Drug: Long-course intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course intravenous antibiotic treatment (≥4 days)
Study: 18468748
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor plus ARB
Study: 12853381
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor therapy
Study: 9481968
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms fentanyl citrate via periodontal ligament injection
Study: 9481968
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo via periodontal ligament injection
Study: 3357006
Drug: VAC (VCR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (VCR, 1.5 mg/m2 IV days 1 and 8; CYC, 275 mg/m2 IV days 1 through 5; ACT‐D, 0.45 mg/m2 IV days 1 through 5 every 28 days for three cycles)
Study: 3357006
Drug: VAC-M (CYC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-M (CYC, 150 mg/m2 IM days 1 through 7; VCR, 2.0 mg/m2 IV day 8; ACT‐D, 1.7 mg/m2 IV day 8 every 21 days for four cycles)
Study: 3357006
Drug: High, single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High, single-dose ACT‐D
Study: 26873491
Drug: Strict dose
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict dose time instructions
Study: 26873491
Drug: Discrepancy between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discrepancy between adherence to dose and dose schedule
Study: 25717121
Drug: Survey administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey administered to all participants after the scans.
Study: 11339516
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg
Study: 27307665
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) with ketamine (5 mg/kg) mixed in mango juice (Group MK)
Study: 27307665
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (1 μg/kg) and oral mango juice (Group DX)
Study: 27307665
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline and oral mango juice (Group C)
Study: 20584595
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 μg (once daily)
Study: 20584595
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 μg (twice daily)
Study: 20584595
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 μg (twice daily)
Study: 20584595
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 375 μg (twice daily)
Study: 20584595
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 μg (twice daily)
Study: 17256309
Drug: Pilocarpine lozenge
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine lozenge (5 mg)
Study: 17256309
Drug: Pilocarpine lozenge
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine lozenge (3 mg)
Study: 17256309
Drug: Salagen tablet
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salagen tablet (control)
Study: 17256309
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge (control)
Study: 8618581
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (117 patients)
Study: 8618581
Drug: Nonrandomized intensive
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrandomized intensive chemotherapy (189 patients)
Study: 8452163
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg twice daily)
Study: 6331150
Drug: 17 g
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 g bran (B)
Study: 6331150
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g bran and fruit (BF)
Study: 26282839
Drug: Morning tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning tobramycin dosing (0800 h)
Study: 26282839
Drug: Evening tobramycin
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening tobramycin dosing (2000 h)
Study: 17601560
Drug: Both morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morning and evening dosing
Study: 16381265
Drug: Wound instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound instillation Group A2 (diclofenac suppository)
Study: 16381265
Drug: Non-wound instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-wound instillation Group B2 (diclofenac suppository)
Study: 9324693
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents (other patients)
Study: 2692810
Drug: Lisuride (1.2-2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (1.2-2.4 mg/day)
Study: 2692810
Drug: Lisuride (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.15 mg/day)
Study: 31961490
Drug: Wait-list, treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list, treatment as usual control condition
Study: 20728083
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 600 μg
Study: 20728083
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 μg
Study: 19637103
Drug: Cocaine/Stimulant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine/Stimulant use
Study: 16713344
Drug: Ropinirole (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (exact dosage and duration not specified)
Study: 11304774
Drug: Accelerated-intensified CEF
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-intensified CEF (HD-CEF14) with G-CSF (cyclophosphamide 1,000 mg/m(2), epirubicin 80 mg/m(2), fluorouracil 600 mg/m(2), administered every 14 days)
Study: 11304774
Drug: Standard CEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CEF (CEF21) (cyclophosphamide 600 mg/m(2), epirubicin 60 mg/m(2), fluorouracil 600 mg/m(2), administered every 21 days)
Study: 3318902
Drug: Adriamycin 70
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 70 mg m‐2 i.v. 3‐weekly for 8 cycles (Regimen A)
Study: 3318902
Drug: Adriamycin 35
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 35 mg m‐2 i.v. 3‐weekly for 16 courses (Regimen B)
Study: 27323446
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (twice a week) and Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Study: 27323446
Drug: Acetylcysteine capsule
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Study: 22458987
Drug: 12-month collaborative
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month collaborative care intervention (problem-solving therapy and/or pharmacotherapy, telephone symptom monitoring/relapse prevention, behavioral activation and patient navigation support)
Study: 20039955
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache (MOH)
Study: 20039955
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache (MOH) and episodic headache (EH)
Study: 18930093
Drug: Intraderal TIV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderal TIV (0.1 ml injection, 9 microg HA/strain)
Study: 18930093
Drug: Intramuscular vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccine (0.5 ml injection, 15 microg HA/strain)
Study: 9162315
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of pulmonary tuberculosis
Study: 3925656
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg nitroglycerin ointment 2%
Study: 28073199
Drug: Intrarectal local
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal local anesthetic administration (lidocaine 5 ml 10%) and lidocaine local spray 15% (Group B)
Study: 28073199
Drug: Periprostatic block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic block anesthesia (lidocaine 10 ml 10%) (Group C)
Study: 24359138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intraligamentary injection + buccal infiltration + IANB
Study: 24359138
Drug: Traditional IANB
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional IANB injection
Study: 20332351
Drug: Twice-daily exenatide
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily exenatide (10 microg)
Study: 12105827
Drug: Gastroenterologist-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroenterologist-administered propofol
Study: 10432168
Drug: Benfluorex (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (150 mg t.i.d.)
Study: 8523379
Drug: Quinapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10-40 mg/day)
Study: 6458582
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg body weight 13‐cis‐retinoic acid
Study: 6458582
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg body weight 13‐cis‐retinoic acid
Study: 6458582
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg body weight 13‐cis‐retinoic acid
Study: 27903087
Drug: Same-day cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day cervical preparation with osmotic dilator and misoprostol
Study: 27903087
Drug: Overnight cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight cervical preparation with osmotic dilator and misoprostol
Study: 25745875
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg
Study: 23342996
Drug: MSP142 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP142 vaccine (50 μg) administered intramuscularly with adjuvant system AS01
Study: 15078748
Drug: Fexofenadine (FEX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (FEX), 180 mg
Study: 15078748
Drug: Montelukast (ML),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (ML), 10 mg
Study: 3141856
Drug: Alpha-2-interferon (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-2-interferon (18 x 10(6) U 3x/week weekly i.m.)
Study: 3141856
Drug: Alpha-2-interferon in
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-2-interferon in combination with vinblastine (0.1 mg/kg every third week i.v.)
Study: 23704674
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus lifestyle
Study: 27803118
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (treatment failure comparison)
Study: 26141467
Drug: 13 mL
Normalized name: ethanol 0.713 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mL 10% tPA
Study: 26141467
Drug: 13 mL
Normalized name: ethanol 0.713 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mL normal saline
Study: 20506261
Drug: Aspirin, NSAID,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, NSAID, and paracetamol use
Study: 19076728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin C and BH(4)
Study: 11442216
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate (20 mg Sb/kg/day) for 10 days
Study: 11442216
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate (20 mg Sb/kg/day) for 20 days
Study: 8061763
Drug: Injection pen
Normalized name: Albiglutide 30 mg powder for solution for injection pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pen for growth hormone administration (Nordiject)
Study: 2853731
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg/day) for 4 weeks
Study: 29474546
Drug: Thrice-weekly intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly intervention messages, plus texted primary care appointment reminders and a monthly text message requesting confirmation of study participation
Study: 29474546
Drug: Texted reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Texted reminders and monthly messages alone
Study: 29474546
Drug: Thrice-weekly intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly intervention messages
Study: 9857618
Drug: ELISA test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA test for detection of antibodies against pertussis toxin
Study: 7634134
Drug: Mouthrinse with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinse with 0.2% chlorhexidine (CHX) and 0.3% triclosan in soya oil, used twice daily for 4 days
Study: 148936
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 1)
Study: 148936
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 2)
Study: 148936
Drug: Phenytoin concentration
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin concentration higher than 14 micromol/l on day 5
Study: 25822861
Drug: Gel hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel hypotonic super-ORS containing zinc (group 2)
Study: 23799163
Drug: Rhinophototherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinophototherapy with topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day, applied twice a week for three weeks.
Study: 23799163
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day (Control group).
Study: 21075562
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice classroom-delivered Drug Awareness intervention
Study: 19996663
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (sevoflurane and intravenous fentanyl)
Study: 11344347
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (withdrawal group)
Study: 9484875
Drug: Grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 400 mg od
Study: 9484875
Drug: Grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 600 mg od
Study: 7910229
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 mg initial dose, then 10 mg daily)
Study: 7910229
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN, 10 mg daily after intravenous for the first 24 hours)
Study: 7910229
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of lisinopril and GTN
Study: 29562612
Drug: Comprehensive nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive nutritional and dietary intervention including vitamin/mineral supplements, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and a healthy gluten‐free, casein‐free, soy‐free (HGCSF) diet
Study: 9771058
Drug: Non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment group (control)
Study: 27430332
Drug: EuroFIT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: EuroFIT program (lifestyle intervention) delivered over 12 weekly, 90-minute sessions combining classroom discussion with graded physical activity.
Study: 9157579
Drug: Desirudin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (10, 15, or 20 mg bid)
Study: 9157579
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU tid)
Study: 8143568
Drug: Nonrigid reclining
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrigid reclining infant seat (3‐h sessions, twice a day for 6‐ to 7‐week period)
Study: 29209863
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - One-time clinical medication review
Study: 16047459
Drug: High-dose omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omeprazole (200 mg/day)
Study: 16047459
Drug: Low-dose omeprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose omeprazole (80 mg/day)
Study: 16047459
Drug: High-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose and low-dose omeprazole
Study: 16047459
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin level <3 g/dL
Study: 10515650
Drug: Active non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active non-steroidal anti-inflammatory drug (NSAID) for 6 weeks
Study: 8536776
Drug: TER 5
Normalized name: Judkins Catheter 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TER 5 mg once in the morning (AM)
Study: 8536776
Drug: TER 5
Normalized name: Judkins Catheter 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TER 5 mg once in the evening (PM)
Study: 8536776
Drug: DOX 4
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOX 4 mg once in the morning (AM)
Study: 8536776
Drug: DOX 4
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOX 4 mg once in the evening (PM)
Study: 1775604
Drug: Tacrine (THA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (THA), a cholinesterase inhibitor
Study: 7274074
Drug: Aminoglutethimide (Elipten)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (Elipten) 250-1500 mg/d by mouth
Study: 7274074
Drug: Aminoglutethimide in
Normalized name: Product containing aminoglutethimide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide in combination with cytostatic drugs
Study: 28657769
Drug: Monurelle Biogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monurelle Biogel® vaginal gel
Study: 17575680
Drug: 2HRZE3/6HE regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2HRZE3/6HE regimen (thrice-weekly direct dosing in the intensive phase and once-weekly with six doses self-administered in the continuation phase)
Study: 15248627
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg orally 1 h before operation and again at 6 and 12 h after the initial dose.
Study: 15248627
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g orally at the same time intervals as ibuprofen.
Study: 15248627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen 800 mg and acetaminophen 1 g.
Study: 15248627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Acetaminophen group).
Study: 9030833
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D receptor genotype
Study: 8315263
Drug: Torasemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (20 mg)
Study: 3548346
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma infusion
Study: 3548346
Drug: Stored plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stored plasma infusion
Study: 3548346
Drug: Daily infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infusion of 1,000 ml of fresh frozen plasma for 7 to 18 days
Study: 28162769
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood granulocyte-colony stimulating factor (G-CSF)
Study: 28162769
Drug: Receiver operator
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiver operator curve analysis for G-CSF